FDA Rejects Over 88,000 Nicotine Products, Crackdown Continues

Aug.05.2022
FDA Rejects Over 88,000 Nicotine Products, Crackdown Continues
FDA rejects manufacturers of over 88,000 nicotine-containing products, including synthetic nicotine, without approval. Evaluation of over 350 products ongoing.

The FDA announced on Wednesday that they have sent "refuse to accept" letters to manufacturers of over 88,000 products containing laboratory-made nicotine.


Stephanie Keith/Getty Images (no translation needed as this is already in standard journalistic English)


Brian Kin, Director of the Center for Tobacco Products, revealed the progress of the FDA's regulation of non-tobacco nicotine sources (i.e. synthetic nicotine). The FDA was authorized earlier this year to regulate synthetic nicotine.


Regulatory gray area.


Brian King stated in a letter to unapproved makers of nasal snuff that "selling or distributing any new tobacco products without pre-market authorization in the U.S. market is illegal." The FDA has not approved any synthetic nicotine products for marketing.


According to regulations set by the FDA, as of July 13th, all unauthorized synthetic nicotine products are considered illegal. Therefore, technically, any manufacturer that has not received FDA approval cannot sell their products after that date.


However, the FDA also noted that it will continue to evaluate over 350 synthetic nicotine products. While many of these products (most of which are e-cigarettes) are technically not allowed to be sold, it is still unclear whether the FDA will remove them from the market upon evaluation. The FDA has exercised enforcement discretion for e-cigarettes containing tobacco-derived nicotine, allowing them to remain on shelves while continuing to weigh their sale.


A buildup process


Jonathan Foulds, a public health science professor specializing in tobacco addiction at Penn State College of Medicine, told Pulse that some manufacturers of synthetic nicotine electronic cigarettes are undoubtedly bad. They exploit regulatory loopholes to stay on the market, with their products mainly targeting teenagers.


Given the tight timeline for compiling evidence, other manufacturers may not have had the opportunity to submit applications to the FDA. "To be honest, I'd be surprised if any of them got authorization," he told Pulse. "It's a lot of work that requires a great deal of information and proper research, which simply can't be completed in just two months." He noted that even electronic cigarette manufacturers that use tobacco-derived nicotine have been unable to meet the FDA's evidence standards, despite having had years to apply for marketing orders.


Statement:


This article is compiled from third-party information and is intended solely for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness or accuracy of the content. The purpose of translating this article is solely for industry discussions and research.


Due to limitations in translation ability, the translated article may not fully convey the intended meaning of the original text. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, or foreign-related expressions or positions.


The compilation of information belongs to the original media and author, and in the event of copyright infringement, please contact us for deletion.


He added, "If they are to withdraw from the market during the review by the agency, it would be fine by me, but they should have enough time to tidy up their applications.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

2Firsts Holds Second PMTA Compliance Training in Shenzhen, Highlighting U.S. Regulatory Framework and Corporate Compliance Capabilities
2Firsts Holds Second PMTA Compliance Training in Shenzhen, Highlighting U.S. Regulatory Framework and Corporate Compliance Capabilities
2Firsts held its second U.S. PMTA compliance training in Shenzhen, providing a systematic overview of the U.S. regulatory framework for e-cigarettes and corporate compliance strategies. Nearly 20 industry professionals from manufacturing, e-liquid and supply-chain companies attended. Participants who passed the exam received compliance certification. Registration for the third training session will open soon, alongside customized corporate training programs.
Mar.09
JTI Korea Introduces Ploom AURA With Four Heating Modes and Four Device Colors
JTI Korea Introduces Ploom AURA With Four Heating Modes and Four Device Colors
JTI Korea announced that its next-generation heated tobacco device Ploom AURA will officially launch in South Korea on April 14. The company held a media event on March 31 at the Fairmont Ambassador Seoul Hotel to unveil the product in Korea for the first time.
Apr.01 by 2FIRSTS.ai
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
A patent published on February 24, 2026, by China Tobacco Hubei Industrial Co., Ltd. introduces a “nicotine jelly” product designed to combine rapid and sustained nicotine delivery. By integrating both free and microencapsulated nicotine, the product aims to address key limitations of traditional nicotine replacement therapy (NRT), while also raising new regulatory and product classification questions.
Innovation
Mar.18
ZYN by IQOS to Roll Out Across Tokyo From May 11 Through IQOS Shops and Lawson
ZYN by IQOS to Roll Out Across Tokyo From May 11 Through IQOS Shops and Lawson
Philip Morris Japan announced on April 23 at a product briefing that ZYN by IQOS, an oral tobacco pouch previously launched in selected areas, will expand sales in Tokyo. The company said the product will be released progressively from May 11 through IQOS shops, Lawson and other outlets in the city. The launch will include four flavors, each offered in Low and Medium intensity levels, for a total of eight products.
Apr.27 by 2FIRSTS.ai
Special Report | Breeze and Glas Seek White House Review as FDA Advances Flavored ENDS Guidance
Special Report | Breeze and Glas Seek White House Review as FDA Advances Flavored ENDS Guidance
Breeze Smoke and Glas, Inc. have separately requested White House review under Executive Order 12866 as the FDA advances draft guidance on flavored ENDS (RIN 0910-ZC78). The guidance aims to clarify evidentiary standards under the statutory “appropriate for the protection of public health” (APPH) framework. The parallel filings highlight industry concern over regulatory predictability, particularly as Glas’s PMTA review status has recently drawn market attention.
Special Report
Mar.03
Philip Morris Limited Launches Delia to Expand IQOS Iluma Consumables Portfolio
Philip Morris Limited Launches Delia to Expand IQOS Iluma Consumables Portfolio
Philip Morris Limited has announced the launch of Delia, the latest addition to its portfolio of heated tobacco and zero-tobacco sticks exclusively compatible with the IQOS Iluma range.
Apr.03 by 2FIRSTS.ai